Announcements Trials
Browse Landscape

Phase

Phase 2 39Phase 3 17Phase 1/2 9Phase 1 7Phase 2/3 4Phase NA 2Phase 4 1

Status

Active not recruiting 4Recruiting 3Completed 3Unknown 2Terminated 2Not yet recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Breast 2

Conditions

Stomach Neoplasms 2HER2-positive Breast Cancer 1Breast Neoplasms 1

Interventions

Cisplatin 13Paclitaxel 11Cyclophosphamide 11Doxorubicin 10Magnetic Resonance Spectroscopy 9Prednisone 8Gemcitabine 8Docetaxel 8Specimen Handling 7Oxaliplatin 7Carboplatin 7Vincristine 6Etoposide 6Capecitabine 6pembrolizumab 5Rituximab 5Radiotherapy 5Leucovorin 5Cytarabine 5Bevacizumab 5atezolizumab 4Trastuzumab 4Platinum 4Nivolumab 4Fluorouracil 4Dexamethasone 4Biopsy 41,2-diaminocyclohexaneplatinum II citrate 4Watchful Waiting 3Taxes 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × Active not recruiting × Trastuzumab × Clear all
NCT04290793 2026-01-07

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Hebei Medical University Fourth Hospital

Phase 2/3 Active not recruiting
113 enrolled
Breast

Breast Neoplasms

NCT05980481 2025-09-29

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

RemeGen Co., Ltd.

Phase 2/3 Active not recruiting
201 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05002127 2025-08-07

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

ALX Oncology Inc.

Phase 2/3 Active not recruiting
127 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05426486 2024-10-30

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Shengjing Hospital

Phase 2/3 Active not recruiting
136 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡